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Abstract
Introduction
A brachiobasilic arteriovenous fistula (BB-AVF) can provide access for haemodialysis in pa-
tients who are not eligible for a more superficial fistula. However, it is unclear whether one-
or two-stage BB-AVF is the best option for patients.
Aim
To systematically assess the difference between both procedures in terms of access matu-
ration, patency and postoperative complications.
Methods
Online search for randomised controlled trials (RCTs) and observational studies that com-
pared the one-stage versus the two-stage technique for creating a BB-AVF.
Results
Eight studies were included (849 patients with 859 fistulas), 366 created using a one-stage
technique, while 493 in a two-stage approach. There was no statistically significant differ-
ence between the two groups in the rate of successful maturation (Pooled risk ratio = 0.95
[0.82, 1.11], P = 0.53). Similarly, the incidence of postoperative haematoma (Pooled risk
ratio = 0.73 [0.34, 1.58], P = 0.43), wound infection (Pooled risk ratio = 0.77 [0.35, 1.68],
P = 0.51) and steal syndrome (Pooled risk ratio = 0.65 [0.27, 1.53], P = 0.32) were
statistically comparable.
Conclusion
Although more studies seem to favour the two-stage BVT approach, evidence in the litera-
ture is not sufficient to draw a final conclusion as the difference between the one-stage and
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the two-stage approaches for creation of a BB-AVF is not statistically significant in terms of
the overall maturation rate and postoperative complications. Patency rates (primary, assis-
ted primary and secondary) were comparable in the majority of studies. Large randomised
properly conducted trials with superior methodology and adequate sub-group analysis are
needed before making a final recommendation.
Introduction
The superiority of haemodialysis (HD) access created by means of an Arteriovenous Fistula
(AVF) in patients with end stage renal disease (ESRD) has been shown before. Stenosis and
thrombosis is less likely to occur in a well-functioning mature AVF when compared to arterio-
venous grafts (AVG) and central venous catheters (CVC), resulting in prolonged patency rates
for AVFs as has been described previously [1]. Also, AVFs carry a lower risk for infection [2,3].
However, around 20%- 50% of all fistulas fail to mature into a useful HD access [4–7].
The preferred location for placing an AVF for the first time is distally at the radius, thus
making it possible to place a second fistula proximally if the first one failed to mature. The
order of preference for creating an AVF [8–10]:
1. Distal Radio-Cephalic
2. Proximal Radio-Cephalic
3. Brachio-Cephalic
4. Brachio-Basilic (transposed Basilic vein)
This order is in agreement with the National Kidney Foundation Kidney Disease Outcomes
Quality Initiative (NKF KDOQI) guidelines [11]. However, fistulas created distally at the wrist
are less likely to mature compared to proximal AVF, at the same time proximal AVF require
less intervention and are likely to last longer [12]. The decision of where to create the AVF can
be helped by preoperative vascular mapping using ultrasound imaging which is expected to im-
prove chances of creating an AVF that will likely mature into a useful dialysis access [13,14].
Placement of a primary forearm fistula is feasible in 40% to 50%, with an upper arm fistula pos-
sible in an additional 25% to 35% of patients [15]. An AVF prevalence of 65% has been rec-
ommended in the KDOQI guidelines for patients undergoing HD [11], this prevalence is
currently higher in Europe (67%- 91%) compared to the US (24%- 47%) [15–18]; however, the
prevalence of AVFs in the US varies significantly among different dialysis units [15,19].
Dagher was the first to describe the use of basilic vein to create an AVF in the upper arm be-
tween the end of basilic vein and the side of the brachial artery to act as access for long term
haemodialysis [20]. Since then, the procedure has seen several changes and modifications.
Superficialisation of a brachiobasilic fistula to make it more susceptive to cannulation can be
achieved either by an elevation technique without mobilisation to bring the vein superficial to
the surgically reconstructed deep fascia and subcutaneous tissue in the anatomic location of
the basilic vein [21], or by a transposition technique by mobilising the entire length of the basi-
lic vein to position the vein anterolaterally through a subcutaneous flap [22].
Some of the debate surrounding brachiobasilic arteriovenous fistulas (BB-AVF) has been fo-
cused on the decision to choose between one-stage vs the two-stage techniques. The one-stage
procedure aims to create a fistula between the basilic vein and the brachial artery in the upper
arm in one procedure. This would require a long incision to gain access and mobilise the basilic
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vein making sure the anastomosis is not placed under tension and no obvious stenosis is pres-
ent proximally. The main advantage of this technique is the shorter waiting time required to
cannulate the fistula. Also the one-stage will prevent the patient from having to undergo anoth-
er procedure and is more cost effective as hospital resources will be used only once. One of the
main disadvantages of this technique is the long incision which will require a longer time to
heal and also carries a higher risk for wound-related complications. Also the procedure takes
longer and is more demanding [23–25]. Moreover, in a study by Anaya-Ayala et al assessing
the anatomy of basilic vein found that only 66% of patients are expected to have a “normal”
basilic vein entering one of two paired brachial veins close to the axilla, while up to 34% will
have an “abnormal” variant that would negatively influence the newly created fistula matura-
tion [26].
The two-stage procedure allows the basilic vein to become arterialised and as such, more re-
sistant to torque and will become easier to mobilise in the second procedure as it gets trans-
formed into a bigger and stronger structure. The hope is that operative difficulty and
complications would be reduced with improved patency rates [27].
This review was designed to systematically assess the difference between both procedures in
terms of access maturation and survival, as well as complications and interventions required to
maintain patency for haemodialysis.
Methods
This systematic review and meta-analysis were conducted according to the Preferred Reporting
Items for Systematic Review and Meta-Analysis (PRISMA) guidelines [28]. No published pro-
tocol exists for this review.
Eligibility criteria
We searched for randomised controlled trials (RCTs) and observational studies that compared
the one-stage technique with the two-stage technique for creating a brachiobasilic arteriove-
nous fistula (BBAVF) for haemodialysis access. Case series and review articles were excluded
from this review.
Search strategy
A search of the literature for relevant studies was conducted in August 2014 using the following
terms: ([“Basilic Vein” OR “Basilic”] AND [“Fistula” OR “Arteriovenous”OR “Access”] AND
“dialysis”). We searched the online databases of: Medline, CINAHL, EMBASE, the Cochrane
library and Google Scholar. We did not restrict our search by publication date or status, howev-
er, we only included studies published in English language and those conducted on humans.
We also searched the bibliographies of included trials for additional studies. A summary of the
study selection process can be found in the PRISMA flow diagram below [Fig. 1]. Studies were
not restricted based on the duration of follow-up.
The main outcome measures for this review were successful maturation and development of
postoperative complications, namely wound haematoma, wound infection and steal syndrome.
Secondary outcomes were primary and secondary patency rates. Definitions for “maturation”,
“primary patency” and “secondary patency” were those specified in individual studies.
Data collection
KB and DH independently extracted the data from included studies on a Microsoft Excel
spreadsheet. Any differences in recording the outcomes of interest were discussed between two
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Fig 1. Prisma Flow Diagram. Eligibility for inclusion was determined by two researchers separately (KB, DH) by going through the abstracts of the relevant
citations. Differences were settled by examining the full article by both authors, and then any remaining uncertainties regarding eligibility of studies were
settled following a discussion with a third author (SRW).
doi:10.1371/journal.pone.0120154.g001
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authors (KB, DH), and if remained unsettled, a third author was consulted to resolve the issue
(SRW). The following characteristics regarding participants were recorded: age, sex, presence
of co-morbidities, primary patency rate, secondary patency rate, maturation rate and postoper-
ative complications (Haematoma, wound infection and steal syndrome). Usability of fistula for
Haemodialysis, time to first use for HD and interventions needed to maintain patency were re-
corded when possible. We also extracted data on compliance with the Society for Vascular Sur-
gery (SVS) recommended standards for reports dealing with arteriovenous haemodialysis
accesses [29]. To this end, we assessed whether studies provided SVS standard-based grading
of factors that affect outcomes and whether studies provided SVS standard-based grading of se-
verity of arteriovenous access complications. The studies’ inclusion and exclusion criteria were
also recorded [Table 1].
Quality assessment for risk of bias
The Downs and Black Tool was used for quality assessment [36]. This tool consists of a total of
27 questions assessing the quality of reporting, external validity and internal validity generating
scores between 0 to 32 which includes a score of 0–5 for sample size justification, however, this
has been modified by awarding one point for studies that reported on sample size calculations,
and zero for those that did not report a methods of sample size calculation. Hence, the modi-
fied score ranged from 0 to 27, with higher scores reflecting higher quality. Details of the quali-
ty assessment can be found in a separate supplemental table [S1 Table].
Data analysis
Statistical analyses were performed using Review Manager version 5.3 [37]. We used the ran-
dom effects model of DerSimonian and Laird [38] to calculate pooled risk ratios for categorical
outcomes measures. The Cochran’s Q test was used to determine statistical heterogeneity
among studies. 95% confidence interval and P-values< 5% were used to determine statistical
significance. We compared between the fixed and random effects modelling to produce a sensi-
tivity analysis aimed at detection of the influence of publication bias of small-study effects[39].
Regarding the meta-analysis we additionally, performed a sensitivity analysis limited to pub-
lished articles only.
Results
Study selection
The results of the study selection process are summarised in the PRISMA flow diagram
[Fig. 1]. We started with a total of 969 citations. Following the removal of duplicates and limit-
ing the search criteria to studies conducted on humans and in English language, we were left
with 295 citations. We then screened the titles of those papers, and found 80 potentially rele-
vant citations. The abstracts of those titles were examined for relevant outcomes, and 22 papers
were evaluated for eligibility criteria, of those 8 citations met our criteria and were included in
the systematic review [21,22,30–35]. Of those 8 studies, 1 was a randomised controlled studies
(RCT). Five were retrospective cohort studies [22,30,31,33,34] and 2 studies were cohort stud-
ies but it was unclear whether they were retrospective or prospective [21,35]. This last citation
was a conference presentation which we included in the review, however we also ran a group of
sensitivity tests excluding the data from this citation and including data extracted from pub-
lished papers only [35].
Six of the included studies compared outcomes between 1-stage versus 2-stage BB-AVF for-
mation techniques, while Hossny et al compared 3 different groups, first group of patients had
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traditional 1-stage basilic vein transposition (BVT), while the second group had 1-stage basilic
vein elevation, and the third group underwent a 2-stage BB-AVF. For the sake of this meta-
analysis, we pooled the first 2 groups from this particular study together [21]. Similarly, Effat
had 3 groups of patients in his conference paper, the first group had standard 1-stage BVT,
whereas the second group had a 2-stage BVT and the last group consisted of patients who had
2-stage superficialization of the basilic vein to create BB-AVF. We pooled the data from the 1-
stage procedures in this last study together in the meta-analysis [35].
Participants
The studies included a total of 849 patients who had 859 fistulas, of those 366 fistulas were
formed using a 1-stage technique, while the remaining 493 fistulas were created in a 2-stage
technique. Overall, 432 were male patients versus 417 female patients. Kakkos et al [31] did not
specify the male to female ratio in the 72 patients who underwent a 2-stage procedure in their
study, however, in the remaining studies, 181 men had 1-stage fistula procedure compared to
164 in the 2-stage group. Similarly, 226 in the 1-stage group were female patients compared to
150 in the 2-stage group. Of the 6 [21,22,30,31,33,35] studies that reported past history of dia-
betes, 143/295 patients were in the 1-stage group while 202/390 were in the 2-stage group. His-
tory of hypertension was reported in 5 studies [21,22,30,33,35], with 123/219 patients in the 1-
stage group and 202/390 in the 2-stage group having the diagnosis. All studies reported on
findings in adult patients with end stage renal disease (ESRD), El-Mallah [32] had the youngest
patients (23.5 ± 5.8 years for the 1-stage group, and 35.8 ± 7.3 years for patients in the 2-stage
group), while the remaining studies included patients in their fifties and sixties [Table 1]. Inclu-
sion and exclusion criteria of studies among other characteristics are outlined in [Table 1].
Main outcomes reported in studies are summarised in [Table 2].
Successful maturation rate
Successful maturation rates were reported in 6 of included studies [21,22,31–34]; the criteria
used for reporting maturation are found in [Table 3]. Those studies had a combined total of
683 fistulas, 301 of those were created in the one stage group, whereas 382 were created in the
two stage group. The difference between the two groups was not significant in pooled analysis
(Pooled risk ratio = 0.95 [0.82, 1.11], 95% CI, P = 0.53) [Fig. 2]. Heterogeneity was detected sta-
tistically (Cochran’s Q = 14.48; degree of freedom (DF) = 5; P = 0.001; I2 = 65%). The signifi-
cance of the results was not altered when using the fixed effects analysis model as a sensitivity
test to detect publication bias (Pooled risk ratio = 0.92 [0.84, 1.01], 95% CI, P = 0.07).
Postoperative complications
Haematoma. The incidence of postoperative wound haematoma was reported in 6 of the
included studies [21,22,30,31,33,35] with a total of 711 fistulas, of those, 295 fistulas were creat-
ed in the 1-stage group and 416 fistulas in the 2-stage group. Analysis of pooled data showed
the difference was not significant (Pooled risk ratio = 0.73 [0.34, 1.58], 95% CI, P = 0.43)
[Fig. 3]. Heterogeneity was not detected statistically (Cochran’s Q = 9.76; degree of freedom
(DF) = 5; P = 0.08; I2 = 49%). The results were not changed significantly when using the fixed
effects analysis model as a sensitivity test to detect publication bias (Pooled risk ratio = 0.67
[0.41, 1.11], 95% CI, P = 0.12). A sensitivity test by excluding the data from the conference
paper by Effat [35] was carried out, and no significant difference was found in the incidence of
postoperative haematoma between the two groups (Pooled risk ratio = 0.67 [0.27, 1.64], 95%
CI, P = 0.38).
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Wound infection. Six of the included studies [30–33,35] reported on the incidence of
postoperative wound infection with a total number of 681 fistulas, 265 of those belonged to the
1-stage group, while 416 consisted of 2-stage fistulas. Meta-analysis of the pooled data showed
the difference between groups not to be significant (Pooled risk ratio = 0.77 [0.35, 1.68], 95%
CI, P = 0.51) [Fig. 4]. There was no evidence of statistical heterogeneity (Cochran’s Q = 5.76;
degree of freedom (DF) = 5; P = 0.51; I2 = 13%). The results were not changed significantly
when using the fixed effects analysis model (Pooled risk ratio = 0.73 [0.39, 1.37], 95% CI,
P = 0.32). A sensitivity test by excluding the data from the conference paper by Effat [35] was
carried out, and no significant difference was found in the incidence of postoperative wound
infection between the two groups (Pooled risk ratio = 0.57 [0.25, 1.27], 95% CI, P = 0.17).
Steal syndrome. Six of the studies [22,30–33,35] reported on the risk of developing signifi-
cant postoperative ischaemia (steal syndrome). Those studies had a combined total of 681
Table 3. Maturation.
Study One
stage
Two
stage
Source of data comments
Vrakas
[22]
36 / 65 49 / 84 Primary failure rates were reported.
This was defined as an AVF that was
never used for dialysis. Primary
failure may have resulted from
inadequate maturation, early
thrombosis, failure of first
cannulation, and other complications
which made AVF unusable.
Successful maturation rates were
derived from these data.
The number of AVFs that required
intervention to assist maturation is
unclear.
Kakkos
[31]
67 / 76 69 / 98 Maturation rates were reported.
Maturation was based upon clinical
judgement (development of basilic
vein dilatation and thrill for a
sufficient length).
Includes fistulas that required
intervention to assist maturation for
dialysis. 7 one stage fistulas
required such intervention and 3
two stage fistulas required such
intervention.
El-Mallah
[32]
12 / 20 18 / 20 Patency at 4 weeks was reported
and we used this figure to determine
successful maturation. The authors
did not provide a definition for
patency.
The number of AVFs that required
intervention to assist maturation is
unclear.
Syed [33] 6 / 29 14 / 77 Maturation rates were reported.
Fistula maturation was defined as
dilation of the vein to allow
cannulation and support dialysis at a
minimum flow rate of 350ml/min for
at least 3 sessions.
The number of AVFs that required
intervention to assist maturation is
unclear.
Agarwal
[34]
55 / 61 62 / 83 Maturation rates were reported.
Maturation was defined as the use of
the fistula for haemodialysis for any
amount of time or, if it was not used,
documentation in surgical or renal
records that the fistula was mature
and ready for use based upon
successful cannulation and/or
physical examination by vascular
surgery.
Includes an unspecified number of
fistulae that needed percutaneous
intervention to assist maturation.
Hossny
[21]
47 / 50 19 / 20 Numbers of fistulas that were
successfully used for dialysis at 6
weeks were reported.
No patients needed reintervention
to assist achievement of successful
dialysis at 6 weeks.
doi:10.1371/journal.pone.0120154.t003
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patients, of those, 265 belonged in the 1-stage group, while 416 belonged in the 2-stage group.
Analysis of pooled data showed the difference was not significant (Pooled risk ratio = 0.65
[0.27, 1.53], 95% CI, P = 0.32) [Fig. 5]. Heterogeneity was not detected statistically (Cochran’s
Q = 3.42; degree of freedom (DF) = 4; P = 0.49; I2 = 0%). The results were not changed signifi-
cantly when using the fixed effects analysis model (Pooled risk ratio = 0.64 [0.29, 1.40], 95%
CI, P = 0.26). A sensitivity test by excluding the data from the conference paper by Effat [35]
was carried out, and no significant difference was found in the incidence of postoperative hae-
matoma between the two groups (Pooled risk ratio = 0.79 [0.32, 1.94], 95% CI, P = 0.60).
Fig 2. Successful maturation rate.
doi:10.1371/journal.pone.0120154.g002
Fig 3. Postoperative Haematoma.
doi:10.1371/journal.pone.0120154.g003
Fig 4. Postoperative wound infection.
doi:10.1371/journal.pone.0120154.g004
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Systematic Review
El-Mallah in his paper titled “Staged basilic vein transposition for dialysis angioaccess” pub-
lished in 1998 [32] compared outcomes in two groups randomly allocated to receive either 1-
stage BVT or 2-stage BVT. The difference in early patency rates was significant and favoured
the 2-stage approach (60% of 1-stage vs 90% of 2-stage, P< 0.05), as well as overall patency
rates at the end of follow-up (50% of 1-stage vs 80% of 2-stage, P< 0.05) [32]. Postoperative
wound infection rate also favoured the 2-stage approach with one case compared to 3 in the 1-
stage group. There was no difference in postoperative aneurysmal dilatation, and there was no
significant ischaemia (steal syndrome) reported in either of the two groups [32].
Hossny looked at the different surgical techniques used in creation of a BB-AVF in 2003
[21]. He compared patency rates and dialysis related complications in 70 patients divided in 3
groups, 30 of those patients had traditional BVT whereas 20 patients had 1-stage BB-AVF with
elevation and the remaining 20 patients had 2-stage fistula with elevation of the vein [21]. Cu-
mulative secondary patency rates were comparable among the 3 groups at 1 year and 2 years;
at 1 year (86.7% for the BVT group, 90% for the 1-stage elevation group and 84.2% for the last
group), while at 2 years (82.8%, 70%, and 68.4%, respectively) [21]. Similarly, no significant dif-
ference was found in his study in postoperative early thrombosis across the groups. Postopera-
tive arm oedema occurred in a total of 14 patients, all of whom had temporary subclavian
access catheters sited on the same arm on which the new fistula was created. All 14 cases were
managed conservatively with success. The difference in developing postoperative haematoma
significantly favoured the traditional BVT approach compared to the two elevation methods
with fewer haematomas reported in the first group. Interestingly, the dialysis staff were more
satisfied with the 1-stage BVT technique, whereas only 53.3% reported satisfaction with the ele-
vation technique (1-stage and 2-stage techniques) (P< .001) [21].
Kakkos et al also tried to answer the question of “What is the Optimal Technique” for per-
forming a BVT in a retrospective study of 173 patients published in 2010 [31]. They found that
the incidence of venous hypertension (17% vs 4%, P = 0.004), wound infection (13% vs 3%, P =
0.012) and all complications (43% vs 11%, P< 0.001) were significantly higher in patients who
had 1-stage BVT when compared to those who had a 2-stage BVT [31]. Time to fistula use in
HD was—expectedly—shorter in the 1-stage group (Median = 68 (49–103) days) compared to
the 2-stage group (Median = 132 (102–166) days). This difference was significant (P< 0.001)
[31]. However maturation rates were similar (85% for the 1-stage groups versus 82% for the 2-
stage group, P = 0.49). Median time to use the fistulas for HD in the 2-stage group was 66 in pa-
tients who developed postoperative complications, compared to 50 days in those who did not
Fig 5. Steal syndrome.
doi:10.1371/journal.pone.0120154.g005
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(P = 0.019). They also found that wound infection occurred more in patients who were operat-
ed under general anaesthetic compared to those who had their procedures done under local
anaesthetic (OR 38, P< 0.001). Also, venous hypertension was found to occur more frequently
in patients who developed postoperative wound haematoma, but the difference was not statisti-
cally significant (18% vs 6%, P 0.12) [31]. A trend was noted towards steal being more common
in patients with previous vascular access than in those who did not have such access (4.9% vs
1.1%, P = 0.19) [31].
Syed et al carried out a similar study comparing the outcomes of 1-stage (29 patients) and
2-stage (77 patients) BVT and published their findings in 2012 [33]. 79% of patients in the 1-
stage group had a history of a previously failed access for HD compared to 51% of the 2-stage
group. They found that the rate of primary failure was comparable between both groups (21%
vs 18%) [33]. In their study, patients who had 1-stage BVT had better patency rates when com-
pared to those who had 2-stage procedures at 1 year (82% vs 67%), 2 years (81% vs 27%) and 3
years (51% vs 18%) respectively. The same finding was reported for secondary patency (91%,
80% and 58% for 1-stage BVT compared to 81%, 61% and 45% for the 2-stage group at 1, 2
and 3 years respectively) [33]. Reintervention rate in this study was 62% for the 1-stage vs 66%
for the 2-stage group. It is worth noting that 87% of the patients in the 2-stage group were
using catheters for dialysis, whereas 55% of the 1-stage group were dialysing through a catheter
at the time of access formation [33].
Ozcan et al published a paper in 2013 with preliminary results from their study comparing
1-stage and 2-stage BVT to create AVF access in HD patients [30]. They retrospectively divided
their patients to those with a basilic vein> 3 mm and who had a 1-stage BVT procedure, and
those with a basilic vein< 3 mm who had a 2-stage procedure. Although the diameter of the
basilic vein was statistically higher in the first group (3.46 ± 0.2 mm) compared to the second
group (2.79 ± 0.1 mm) (P< 0.005), the rate of fistula maturation was significantly lower in the
first group (66% vs 77%, P< 0.005) [30]. Also, postoperative complications were significantly
higher among the first group of patients who had 1-stage BVT. Thrombosis occurred in 34%
compared to 23% of patients who had a 2-stage procedure, haemorrhage in (36% vs 14%) and
haematoma in (17% vs 6%) respectively. Time required for the fistula to mature was signifi-
cantly shorter in the first group (Mean 41 ± 14 days) compared to the second group (Mean 64
± 28 days) (P< 0.05) [30]. Early interventions ( 10 days) for fistula thrombosis occurred
more frequently in the first group (21% vs 12%, P< 0.05), although there was no significant
difference in terms of late interventions ( 10 days) required to deal with access thrombosis
(20% in the first group vs 22% in the second) [30]. Also they reported superior primary patency
rates at 6, 12, 18, 24, 30 and 36 months for those who had 2-stage BVT fistulas compared to the
first group of patients (1-stage 83%, 70%, 68%64%, 60% and 57% versus 88%, 84%, 80, 73%,
71% and 69% for the 2-stage respectively). Similarly, the 1-stage had lower secondary patency
rates at 6, 12, 18, 24, 30 and 36 months when compared to the 2-stage group (85%, 76%, 74%,
72%, 70% and 66% versus 94%, 90%, 84%, 82%, 80% and 77% respectively) [30].
Similarly, Vrakas et al evaluated the difference in outcomes between 1-stage (65 fistulas)
and 2-stage (84 fistulas) BB-AVFs performed in 141 patients [22]. They performed ultrasound
scans 4–6 weeks after the first stage procedure to determine if a second stage was required. Pa-
tients who had their fistulas created in a 1-stage approach had a bigger preoperative basilic vein
diameter (4.0 ± 1.1 mm vs 3.6 ± 1.3 mm, P = 0.041) [22]. There was no difference in primary
failure between the groups (45% vs 42%, P = 0.718), however the 1-stage BB-AVF had signifi-
cantly lower primary (71% vs 87%; P = 0.034), assisted primary (77% vs 95%; P = 0.017), and
secondary (79% vs 95%; P = 0.026) functional patency rates compared to the 2-stage BB-AVF
[22]. Multivariate Cox regression analysis showed that the 1-stage procedure was 3.2 times
more likely to fail (P = 0.028), and male gender was associated with loss of access (P = 0.054).
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66% of the fistulas in the first group were used successfully for HD compared to 60% in the 2-
stage group (P = 0.407), and intervention before first successful HD session was equivalent be-
tween both groups (21% vs 11%, P = 0.201) [22]. Overall, 93 (62%) fistulas were successfully
used for HD (66% 1-stage vs 60% 2-stage; P = 0.407), of the remaining 56 (38%), 19 fistulas
(34%) failed before needling, 2 (4%) received a renal transplant, 7 (13%) died, and 28 (50%)
BBAVFs remain patent in patients awaiting to start HD [22].
Agarwal et al examined the outcomes of 1-stage vs 2-stage BVT AVF. They included pa-
tients who underwent percutaneous angioplasty (assisted maturation) in calculating the overall
maturation rate which was 90% for the 1-stage group (55/61 patients) compared to 75% of the
2-stage group (62/83 patients) (P = 0.02). Subgroup analysis showed that both men (54/66 pa-
tients) and women (64/78) in this study had a maturation rate of 82% (P = 0.97)[34]. Primary
unassisted patency rates were comparable between the groups (69%, 52%, 26%, and 7% for the
1-stage BVT at 3 months, 6 months, 1 and 2 years; compared to 58%, 35%, 13%, and 0% of the
2-stage group, respectively (p = 0.12) [34]. Similarly, no significant difference was found in sec-
ondary patency on an intent to-treat basis (86%, 75%, 69%, and 57% at 1, 2, 3, and 4 years for
1-stage group; compared to 76%, 71%, 49%, and 25% of the 2-stage group, respectively);
(p = 0.12) [34]. The intensity of percutaneous interventions in their study was 1.84/patient-
year of dialysis (PYD) for the 1-stage group versus 2.15/PYD for the 2-stage group (P = 0.57)
[34]. They suggested that although the 2-stage BB-AVF technique resulted in modest reduction
in maturation and patency rates, it should still be favoured to the use of synthetic grafts in pa-
tients who would not be suitable for a 1-stage BB-AVF procedure [34].
The number of AVFs that failed to progress from the first stage to the second stage in the
two-staged BVT approach were unclear in four studies [22,30,34,35]. In the remaining four, El-
Mallah [32] reported 1/20 patient which had an occluded shunt, while Hossny [21] also had 1/
20 patient failing to progress due to spontaneous thrombosis within the first 4 weeks postoper-
atively. Syed [33] had 2/77 patients that never progressed to the second stage of the procedure.
Kakkos [31] reported that 26/98 of his patients never had a second stage procedure (throm-
bosed (n = 4), failed to mature and was abandoned during the re-exploration (n = 12), patient
refused the procedure (n = 3), lost to follow-up (n = 1), died (n = 2), venous hypertension
(n = 2), venous monomelic neuropathy (n = 1) requiring ligation, moved out of state (n = 1)).
Number of interventions required to maintain patency or to improve the fistula maturation
rates were not reported clearly in all studies. Hossny reported that in the one-stage group one
patient underwent ligation and another had a surgical revision, same numbers occurred in the
two-stage group. All ligations were done to treat venous hypertension, whereas all revisions
were performed to improve poor flow [21]. Kakkos reported that in the two-stage group 6 pa-
tients had endovenous angioplasty interventions, 3 had surgical revisions compared to 3 pa-
tients and 1 patient in the one-stage group respectively [31]. Syed et al performed 37
angioplasty interventions, 9 surgical revisions and 5 thrombectomy procedures in their two-
stage group, compared to 14, 2 and 2 patients respectively [33]. The remaining studies either
did not report data related to fistula salvage procedures or it was reported in poor details mak-
ing it difficult to quantify those interventions.
With the exception of the studies by El-Mallah et al [32] and the one by Vrakas et al [22]
which both reported significantly superior patency rates in the two-stage groups, and the paper
by Syed [33] which conversely reported a significantly better patency rates in the one-stage BVT
group, the remaining studies all reported comparable patency rates [21,30,31,34,35] [Table 2].
However it is important to point out that patency rate data were reported as percentages with the
lack of clearly identifiable denominators in the majority of those studies, thus making pooling
those data in a meta-analysis not feasible. Also, definitions used in individual studies included in
this review for patency rates (primary, assisted primary and secondary) differed significantly.
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Discussion
The number of patients with end stage renal disease (ESRD) requiring haemodialysis (HD) is
steadily rising, a trend that is expected to continue [2]. A well-functioning AVF is superior to
grafts and central catheters in providing access for haemodialysis efficiently and at the same
time with the least rate of access related complications. This has lead vascular surgeons to re-
sort to the basilic vein which by virtue of its anatomical position is less likely to be damaged by
repeated cannulation as with the more superficial veins of the arm and forearm. However, a
consensus on how to form a brachiobasilic AVF does not exist as some surgeons choose to do
this in a one-stage operation, while others prefer a two-stage procedure with the first procedure
usually involving making the anastomosis between the basilic vein and the brachial artery,
while in the second stage the arterialised vein is mobilised and brought closer to the skin sur-
face to facilitate cannulation for HD sessions.
This review identified eight studies [21,22,30–35], including data from a conference paper
[35] in order to increase the rigour of the review. The pooled data referred to 849 patients with
a total of 859 fistulas, 366 of those fistulas belonged to patients who underwent a 1-stage BB-
AVF, while 493 fistulas were performed using a 2-stage technique to create the access. The data
from 6 of the included studies [21,22,30,31,33,35] were used to compare the difference between
the two groups in developing postoperative haematoma which was not significant (Pooled risk
ratio = 0.69 [0.30, 1.56], 95% CI, P = 0.37). Excluding the data from the conference paper by
Effat [35] in a sensitivity test did not alter the result (Pooled risk ratio = 0.61 [0.23, 1.60], 95%
CI, P = 0.31).
Incidence of postoperative wound infection was reported in five studies [30–33,35], and the
difference between the 1-stage group and the 2-stage group was not found to be significant
(Pooled risk ratio = 0.82 [0.31, 2.18], 95% CI, P = 0.69). This remained unchanged when ex-
cluding the data by Effat [35] in a sensitivity test (Pooled risk ratio = 0.57 [0.21, 1.51], 95% CI,
P = 0.27).
Similarly, the difference between the two groups was not found to be significant when it
came to postoperative ischaemia (steal syndrome) in the 6 studies which reported this compli-
cation [22,30–33,35] (Pooled risk ratio = 0.51 [0.20, 1.30], 95% CI, P = 0.16). We performed a
sensitivity test by excluding the data by Effat [35] from the pooled data, and the result was not
altered (Pooled risk ratio = 0.63 [0.23, 1.69], 95% CI, P = 0.35).
Ozcan et al [30] allocated patients to groups based on vein diameter, with those with basilic
vein> 3 mm receiving a 1-stage BVT, while patients with basilic vein< 3 mm received a 2-
stage BVT. Even with this seemingly advantageous difference in favour of the 1-stage approach,
they reported superior patency rates and maturation rates in patients who had a 2-stage proce-
dure with primary patency at 1, 2 and 3 years for the 1-stage group of (70%), (64%), and (54%)
versus (84%), (73%), and (69%) in the 2-stage group. Secondary patency rates at 1, 2 and 3
years for the 1-stage group were (76%), (72%), and (66%) versus (90%), (82%), and (77%) in
the 2-stage group.
Similarly, Vrakas et al reported a smaller mean vein diameter of (3.6 ± 1.3 mm) for the 2-
stage, versus (4.0 ± 1.1 mm) fistulas created in the 1-stage group, yet their results favoured the
2-stage approach with primary functional patency at 1 and 2 years for the 1-stage group of 71%
and 53% versus 87% and 75% in the 2-stage group. Assisted Primary functional patency at 1
and 2 years for the 1-stage group was 77% and 57% versus 95% and 77% in the 2-stage group,
while secondary functional patency at 1 and 2 years for the 1-stage group was 79% and 57%
versus 95% and 77% in the 2-stage group.
Conversely, in study by Agarwal et al [34], their patients in the 1-stage group achieved better
maturation rate than those who had a 2-stage BVT fistulas (90% vs 75%, P = 0.02). They did
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not include any analysis between the two groups based on vein diameter. Vein diameter has
been shown to negatively influence maturation and patency rates in AVFs, and is one of the
main predictors of those outcomes in fistulas [40,41], and indeed has been shown to be the
only independent predictor of maturation in some studies[42,43]. Syed et al reported similar
findings with better primary and cumulative patencies in the 1-stage group with primary pa-
tency at 1, 2 and 3 years (82% vs 67%), (81% vs 27%) and (51% vs 18%), while (secondary pa-
tency at 1, 2 and 3 years (91%, 80% and 58% for 1-stage BVT and 81%, 61% and 45% for the 2-
stage group. Variations in vein diameter between the two groups were not reported in
this study.
Kakkos et al [31] did not find a significant difference in maturation between the two groups,
as 15% of fistulas in the 1-stage group did not mature, compared to 18% in the second group
(P = 0.49). They did however find significant difference in developing postoperative haema-
toma (13% vs 3%, P = 0.012), venous hypertension (17% vs 4%, P = 0.004) and overall compli-
cations (43% vs 11%, P< 0.001), all in favour of the 2-stage BVT technique.
Kim et al compared the 2-stage approach to all other AVF procedures including 1-stage
BVT, radiocephalic and brachiocephalic fistulas. All of the 2-stage BB-AVFs in their study suc-
cessfully matured compared to a pool consisting of all different types that showed a combined
maturation rate of 52% (P = 0.001). Fistula failure occurred in 7% of the 2-stage BVT compared
to 59% of other fistulas (P = 0.001), and more 2-stage BVT fistulas were used successfully for
HD compared to all other fistula types (87% vs 48%, P = 0.024). Also, the patency rate at 1 year
was superior in the 2-stage group compared to other AVFs (91% vs 47%, P = 0.003).
One of the limitations of this review is the low number of randomised trials included—1
study was randomised—while the remaining 7 were cohort studies. Most of these studies were
retrospective. Another limitation is the variation in surgical approaches, those variations in-
clude technical differences in performing the procedure, as well as differences in equipment
used and expertise among participating surgeons. Those limitations can be addressed by con-
ducting a large randomised multi-centre trial that would adhere to a rigid protocol in patients’
selection process and performing the procedures. Another limiting factor is the lack of suffi-
cient sub-group analysis among included studies, particularly analysis taking into account fac-
tors that are known to be associated with fistula maturation such as vein diameter. Finally, we
highlight that included studies were not compliant with SVS reporting recommendations re-
garding baseline factors that affect outcomes or severity of complications.
Conclusion
Although more studies seem to favour the 2-stage BVT approach, evidence in the literature is
not sufficient to draw a final conclusion as the difference between the 1-stage and the 2-stage
approaches for creation of a BB-AVF is not statistically significant in terms of the overall matu-
ration rate and postoperative complications. Patency rates (primary, assisted primary and sec-
ondary) were comparable in the majority of studies. Large randomised properly conducted
trials with adequate sub-group analysis are needed before making a final recommendation. Fu-
ture studies should aim for compliance with established reporting standards.
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